Seeking Alpha

Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is...

Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmasset on Friday.
Comments (2)
  • phoneranger
    , contributor
    Comments (350) | Send Message
     
    What if you owned more GILD than VRUS? Some folks did. http://bit.ly/svFPCi
    21 Nov 2011, 09:43 AM Reply Like
  • Chuck Carnevale
    , contributor
    Comments (7198) | Send Message
     
    Is $GILD undervalued? See F.A.S.T. Graphs: http://bit.ly/vfyDTX
    21 Nov 2011, 11:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs